The new therapy can only handle people that are blind in one eye, mainly because it relies on making use of stem cells from their remaining wholesome eye. However, Sooner or later, the workforce would like to produce the procedure to allow them to use stem cells from organ donors, rather than making
Perspective book Webinar Webinar Vital issues when selecting a CDMO partner for cell therapy production Like many therapeutic manufacturing workflows, each and every stage inside the mRNA procedure builds upon the prior phase.
? ?? ?? ??? ???? ??, ??? ???? ??? ????. ??
?? ??? ?? ? ??? ??? ???